TSTickerStarGet alerts

GT Biopharma files DEF 14A for Special Meeting on Nov. 11, 2026 to approve charter amendments and Series M private placement issuance

GT Biopharma filed a definitive proxy statement for a Special Meeting of Stockholders to be held on November 11, 2026, at 11:00 a.m. Pacific Time in Los Angeles. Stockholders will be asked to approve (i) an amendment and restatement of the Charter to eliminate sections referencing obsolete preferred stock series, (ii) an increase in authorized common stock from 25,000,000 to 250,000,000 shares, (iii) the issuance of 19.99% or more of outstanding common stock in connection with the September 14, 2026 Securities P...

Share this story

Key takeaways

  • Special Meeting of Stockholders set for November 11, 2026 at 11:00 a.m. Pacific Time in Los Angeles; record date September 30, 2026 with 2,061,052 shares of common stock outstanding.

  • Proposal No. 2 would increase authorized common stock tenfold, from 25,000,000 to 250,000,000 shares, with no change to the 1,500,000 authorized preferred stock.

  • Proposal No. 3 seeks stockholder approval under Nasdaq Listing Rule 5635(b)/(d) for the issuance of 19.99% or more of outstanding common stock related to the September 14, 2026 Securities Purchase Agreement with Private Placement Investors (Series M Preferred Stock and Warrants).

  • Series M private placement terms: up to 8,611.111 shares of Series M 10% Convertible Preferred Stock, aggregate stated value of $8,611,111.11 for $7,750,000 cash; initial conversion price $6.10 with a $1.282 floor; 10% per annum dividends until September 13, 2027, escalating to 12% thereafter, paid quarterly in cash or shares; rank senior to all classes other than pari passu Series L Preferred Stock.

  • Greenshoe Rights of up to $34,675,615 aggregate stated value for $31,208,054 additional purchase price would be available subject to stockholder approval of Proposal No. 3, supported by Vesting Warrants.

  • Ownership impact: if Proposal No. 3 is approved, the Private Placement Investors would own approximately 44% of voting power on conversion of Series M only, and approximately 61% if all Common Stock Warrants are exercised for cash.

  • Common Stock Warrants and Vesting Warrants each have an initial exercise price of $6.10 per share and a five-year exercise term; without Proposal No. 3 approval, a 19.99% Beneficial Ownership Limitation and a 360,695-share Exchange Cap apply.

Key metrics

Shares of Common Stock outstanding (Record Date)September 30, 2026
2,061,052
Quorum threshold (1/3 of outstanding)September 30, 2026
687,018
Current authorized Common StockPre-amendment
25,000,000
Proposed authorized Common StockPost-amendment (effective on or before November 11, 2027)
250,000,000
Authorized Preferred StockCurrent
1,500,000
Series L Preferred Stock designatedCurrent
30,630
Series M Preferred Stock designatedCurrent
43,287
Aggregate Series M shares initially issuable under SPASeptember 14, 2026
8,611.111

Disclosure changes

  • Charter amendment to eliminate obsolete preferred stock references

    Proposal No. 1 seeks stockholder approval to amend and restate the Charter to eliminate sections referencing Series A, B, C, D, E, F, G, H, I, J-1 and K Preferred Stock, all of which were previously eliminated via Certificates of Elimination filed with the Delaware Secretary of State on September 2, 2026.

    Housekeeping amendment that does not change the number of authorized preferred shares (remains 1,500,000) but cleans the Charter of references to retired series.
  • Increase in authorized Common Stock from 25,000,000 to 250,000,000

    Proposal No. 2 would increase authorized common stock 10x from 25,000,000 to 250,000,000 shares to support general corporate purposes and potential Series M Preferred Stock conversions and Warrant exercises; Board-approved September 30, 2026; must be implemented on or before November 11, 2027 if approved.

    10x increase in authorized common shares enables additional capital raises, acquisitions, consulting/employment arrangements, and is required to support conversion of Series M Preferred and exercise of Warrants; could result in significant dilution to current stockholders.
  • Securities Purchase Agreement (Series M private placement)

    On September 14, 2026 (amended September 18, 2026), the Company entered into a Securities Purchase Agreement with Private Placement Investors for up to 8,611.111 Series M 10% Convertible Preferred Stock plus Common Stock Warrants and Vesting Warrants; aggregate stated value $8,611,111.11 for $7,750,000 cash; Greenshoe Rights up to additional $34,675,615 stated value for $31,208,054; initial conversion price $6.10 with $1.282 floor.

    Material dilutive financing requiring Nasdaq Rule 5635(b)/(d) stockholder approval (Proposal No. 3); approval would give investors approximately 44% voting power (preferred only) and up to approximately 61% (with warrants exercised).
  • Series M Preferred Stock terms

    Series M Preferred Stock bears 10% per annum dividends until September 13, 2027 and 12% thereafter, payable quarterly in cash or shares; ranks senior to all classes except pari passu Series L Preferred Stock; has no voting rights other than class-vote protections; convertible at $6.10 with $1.282 floor subject to Beneficial Ownership Limitation and Exchange Cap absent stockholder approval.

    Defines new senior equity class with above-market dividend rate and anti-dilution mechanics; converts into significant common share block contingent on Proposal No. 3 approval.
  • Registration Rights Agreement

    On September 14, 2026, the Company entered into a Registration Rights Agreement requiring filing of a resale registration statement within 30 days covering Common Stock issuable upon conversion of Series M Preferred Stock and exercise of the Warrants, with effectiveness within 60 days (or 90 days if full SEC review).

    Registration obligation increases float of resalable shares tied to Private Placement Investors once conversion/exercise rights unlock.
  • Voting Agreement

    All officers and directors entered into a Voting Agreement to vote their shares in favor of Proposal No. 2 (authorized share increase).

    Insider commitment to support the authorized share increase proposal; reduces execution risk on Proposal No. 2 but Proposal No. 3 voting is not subject to the same lock-up.

Primary source

TickerStar generated this brief from an official company, investor-relations, earnings-call, or regulatory source. Review the primary material before making an investment decision.

Open SEC filing

Follow GTBP in real time

Get material earnings, filing, IR, and earnings-call alerts by email.

Create a free alert